While participants currently enrolled in the studies will continue their treatment, the company labeled the pause a precautionary measure. Management stated the observed adverse events align with the drug’s known safety profile, yet noted these specific incidents had not surfaced during previous clinical testing. Xenon is now evaluating dosing modifications intended to mitigate these risks and expects the suspension to be temporary.

Despite the setback in psychiatric research, the company continues to push forward with other applications for the drug. On the same day as the announcement, Xenon submitted a new drug application to the Food and Drug Administration seeking approval for azetukalner as a treatment for focal seizures.